Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
104.00    0.80 (0.78%)
Bid:
100.20
Ask:
105.80
Spread: 5.60 (5.589%)
Market Cap: £170.50m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Interim Management Statement

12 May 2011 07:00

RNS Number : 4433G
Yule Catto & Co PLC
12 May 2011
 



12 May 2011

 

Yule Catto & Co plc (the "Group") 

 

Interim Management Statement

 

At this afternoon's AGM of Yule Catto & Co plc, the international producer of speciality chemicals, Chairman Peter Wood will make the following statement which also comprises the Group's interim management statement for the period 1 January 2011 to date.

 

The Group's earnings for the first quarter were well ahead of the same period last year excluding any impact of the PolymerLatex acquisition, and the Board's expectations for financial performance for 2011 remain unchanged.

 

Overall demand in Yule Catto's Polymer business was solid. Asian demand was strong through the quarter, whilst Europe firmed after a slow start in the UK. Ongoing very substantial monomer price increases have had to be passed on to customers, resulting in the usual temporary margin compression as the increases are recovered and target unit margins per tonne restored. Consequently, although volumes increased in Polymers and turnover was strongly ahead, operating profit was flat year on year in the first quarter. Whilst Europe lagged the prior year, Asia was ahead, despite, as expected, profits being temporarily constrained by capacity during the quarter. This position will be resolved in the course of the second quarter with the new 15,000 tonne nitrile expansion coming on line and some spare capacity in the acquired PolymerLatex nitrile assets. In April, the existing Yule Catto polymer business performed ahead of prior year.

 

The acquisition of PolymerLatex completed at the end of March as anticipated. Integration planning progressed through the first quarter and is now being implemented. Post acquisition, the synergy potential has been confirmed, and management remain highly confident that at least £20m of synergies will be delivered as disclosed at the time of the acquisition announcement and to the same timetable. Regular updates on progress in delivering these synergies will be provided to investors, with the first update to be delivered with the group's half year results in August. As at the date of this statement, actions taken to date have already delivered synergies with an annual run rate value of approximately £2m.

 

PolymerLatex itself traded comfortably ahead of last year in the first quarter, and this has continued through April. The business benefited from good demand in central Europe for latex and volume growth in its Malaysian nitrile facility. Plans are already being developed for very substantial increases in capacity in Asia for nitrile and SBR latex to be brought on line before the end of 2012.

 

In the Group's other businesses in the first quarter, the Pharma division performed well ahead of what was a very weak result in the same period last year, whilst William Blythe continued to grow profits strongly.

 

Net debt at the end of the quarter stood at £235m reflecting the impact of the acquisition of PolymerLatex, in line with the Group's forecasts at the time of the acquisition announcement.

 

- Ends -

 

ENQUIRIES:

 

Yule Catto & Co plc

Tel: 01279 442791

Adrian Whitfield, Chief Executive

David Blackwood, Group Finance Director

MHP Communications

Tel: 020 3128 8100

Andrew Jaques

John Olsen

Ian Payne

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSLFFLFERILLIL
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.